Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad

Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been a...

Full description

Saved in:
Bibliographic Details
Published inLaboratory animal research Vol. 35; no. 1; pp. 30 - 9
Main Authors Kang, Ju-Hee, Jang, Yeong-Su, Lee, Ha Jung, Lee, Chang-Yong, Shin, Dong Yun, Oh, Seung Hyun
Format Journal Article
LanguageEnglish
Published London BioMed Central 21.12.2019
BMC
한국실험동물학회
Subjects
Angiogenesis
Annexin V
Antibodies
Apoptosis
Biomedical and Life Sciences
c-Myc protein
Cancer
Cancer therapies
Cell cycle
Cell differentiation
Cell proliferation
Cell survival
Chemoresistance
Chemotherapy
Cyclin D1
Dosage
Gene expression
Gene regulation
Kinases
Leukocytes
Life Sciences
Lung cancer
Medical prognosis
Medical research
Metastases
Myc protein
NSCLC
Poly(ADP-ribose) polymerase
Ribose
Side effects
STAT3 inhibitor
Stat3 protein
STX-0119
Survivin
Transcription
Tumor cell lines
Tumors
Xenograft
Xenografts
수의학
United States > US
Xenograft
NSCLC
STAT3 inhibitor
STX-0119
Cancer
Online AccessGet full text
ISSN2233-7660
1738-6055
2233-7660
DOI10.1186/s42826-019-0030-0

Cover

Abstract Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics.
AbstractList Abstract Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics.
Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics.
Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics.Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics.
Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics. KCI Citation Count: 0
ArticleNumber 30
Author Shin, Dong Yun
Oh, Seung Hyun
Jang, Yeong-Su
Kang, Ju-Hee
Lee, Ha Jung
Lee, Chang-Yong
Author_xml – sequence: 1
  givenname: Ju-Hee
  surname: Kang
  fullname: Kang, Ju-Hee
  organization: College of Pharmacy, Gachon University
– sequence: 2
  givenname: Yeong-Su
  surname: Jang
  fullname: Jang, Yeong-Su
  organization: College of Pharmacy, Gachon University
– sequence: 3
  givenname: Ha Jung
  surname: Lee
  fullname: Lee, Ha Jung
  organization: College of Pharmacy, Gachon University
– sequence: 4
  givenname: Chang-Yong
  surname: Lee
  fullname: Lee, Chang-Yong
  organization: College of Pharmacy, Gachon University
– sequence: 5
  givenname: Dong Yun
  surname: Shin
  fullname: Shin, Dong Yun
  organization: College of Pharmacy, Gachon University
– sequence: 6
  givenname: Seung Hyun
  orcidid: 0000-0003-3678-2772
  surname: Oh
  fullname: Oh, Seung Hyun
  email: eyeball@hanmail.net
  organization: College of Pharmacy, Gachon University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32257917$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002547058$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kktv1DAUhSNUREvpD2CDIrGBReDaTvxgUWlU8RipEhIMa8uxnYynqR3sBMS_xzMppa0E9sJX9neOr-XztDjywduieI7gDUKcvk015phWgEQFQKCCR8UJxoRUjFI4ulMfF2cp7SCPBhip4UlxTDBumEDspGjXfutaN7ngy9CVXzerDSmT670anO9L582sbSrVGMYpJJcrb8o0j2O0KeWDPoaf03YvHebMa-W1je_KPgRzQFtlnhWPOzUke3aznhbfPrzfXHyqLj9_XF-sLitNCZ0qIQTXyiqCFAdgGmsqlNAEDFK1UYiDAaHamulW87ZFWtCuAatAMIahJuS0eL34-tjJK-1kUO6w9kFeRbn6sllLWmOEBc_semFNUDs5Rnet4q-D4LARYi9VnJwerBQdFwTlaUDX2lDekLbGDCGBTM1xl73OF69xbq-t0dZPUQ33TO-feLfNPf2QDDhqsMgGr24MYvg-2zTJa5e0HQblbZiTxIQz2jT5zoy-fIDuwhzzZ2WqqSnHDaJ7wxd3O7pt5c-3ZwAtgI4hpWi7WwSB3KdLLumSOV1yny4JWcMeaLSb1D44-VFu-K8SL8qUb_G9jX-b_rfoN0104QE
CitedBy_id crossref_primary_10_3390_v13112199
crossref_primary_10_3389_fonc_2022_988626
crossref_primary_10_1186_s12917_024_04429_6
crossref_primary_10_2174_0113895575254012231024062619
crossref_primary_10_3390_ph14121287
crossref_primary_10_1016_j_bbagen_2023_130486
crossref_primary_10_2147_JEP_S494158
crossref_primary_10_1016_j_canlet_2025_217501
crossref_primary_10_4103_jofs_jofs_330_23
crossref_primary_10_1016_j_biopha_2022_113137
crossref_primary_10_1111_jcmm_17102
crossref_primary_10_4103_2221_1691_311770
crossref_primary_10_1016_j_biopha_2020_111077
crossref_primary_10_1248_cpb_c23_00718
crossref_primary_10_3390_biomedicines9080876
crossref_primary_10_3390_ijms22094797
crossref_primary_10_3390_ijms21155502
crossref_primary_10_1016_j_fbio_2021_101038
crossref_primary_10_1186_s12935_024_03463_6
crossref_primary_10_1016_j_ejogrb_2024_01_013
crossref_primary_10_3390_biom10101380
crossref_primary_10_3390_cells9051086
crossref_primary_10_3390_nu15082007
crossref_primary_10_1007_s43440_021_00345_w
Cites_doi 10.3892/ijo.2013.1916
10.1158/0008-5472.CAN-08-4323
10.3322/caac.21262
10.1016/j.ccr.2011.03.018
10.1093/annonc/mdq207
10.1200/JCO.2013.52.8414
10.1016/j.ccr.2009.01.002
10.3390/cancers6020897
10.7150/thno.35528
10.1016/S1074-7613(00)80011-4
10.1002/path.1253
10.1038/nrc2734
10.5483/BMBRep.2019.52.7.152
10.1016/j.ejso.2013.11.012
10.4236/jct.2015.68078
10.1200/JCO.2012.45.6004
10.5625/lar.2017.33.2.114
10.1038/nm0605-595
10.1172/JCI35213
10.1038/nrc3818
10.1021/acschembio.5b00945
10.1016/j.lungcan.2015.09.014
10.1016/j.semcdb.2008.06.005
10.3892/ijo.2012.1568
10.1038/nrc3237
10.1038/nri1995
10.1186/2050-7771-1-5
10.1038/nrclinonc.2018.8
10.1016/j.imlet.2017.07.005
10.1007/s00109-012-0869-0
10.1517/14712598.6.3.231
10.1021/ml1000273
10.1016/j.bbrc.2019.03.156
10.1093/jnci/djm135
10.3322/caac.21387
10.3390/cancers6010494
ContentType Journal Article
Copyright The Author(s) 2019
The Author(s) 2019.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Copyright_xml – notice: The Author(s) 2019
– notice: The Author(s) 2019.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
DBID C6C
AAYXX
CITATION
NPM
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
ACYCR
DOI 10.1186/s42826-019-0030-0
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
Korean Citation Index
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic

PubMed

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Zoology
EISSN 2233-7660
EndPage 9
ExternalDocumentID oai_kci_go_kr_ARTI_6421298
oai_doaj_org_article_9f8931313d0c4cd6853b4271191d482f
PMC7081529
32257917
10_1186_s42826_019_0030_0
Genre Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Gachon University
  grantid: GCU-2019-0313
  funderid: http://dx.doi.org/10.13039/501100002631
– fundername: National Research Foundation of Korea
  grantid: NRF-2018R1A6A3A01012342
  funderid: http://dx.doi.org/10.13039/501100003725
– fundername: ;
  grantid: NRF-2018R1A6A3A01012342
– fundername: ;
  grantid: GCU-2019-0313
GroupedDBID 0R~
5-W
8JR
8XY
9ZL
AAFWJ
AAYYP
ADBBV
ADUKV
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BENPR
BFQNJ
BHPHI
BMC
C6C
CCPQU
DBRKI
EBS
EF.
EJD
GROUPED_DOAJ
H13
HCIFZ
HYE
KQ8
M48
M7P
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PUEGO
ROL
RPM
RSV
SOJ
TDB
AAYXX
CITATION
ABDBF
ACRMQ
ACUHS
ADRAZ
C24
GW5
M~E
NPM
8FE
8FH
ABUWG
AZQEC
DWQXO
GNUQQ
LK8
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ABVAZ
ACHIH
ACYCR
AFGXO
AFNRJ
ID FETCH-LOGICAL-c636t-9998caea31a8007c2c69a9c30d1a4da180d09ab47cbc8bb1c96f50ea097720433
IEDL.DBID M48
ISSN 2233-7660
1738-6055
IngestDate Sun Jan 07 03:19:08 EST 2024
Wed Aug 27 01:34:51 EDT 2025
Thu Aug 21 14:35:01 EDT 2025
Fri Sep 05 12:27:40 EDT 2025
Fri Jul 25 11:51:03 EDT 2025
Thu Jan 02 22:58:54 EST 2025
Tue Jul 01 03:06:42 EDT 2025
Thu Apr 24 22:57:23 EDT 2025
Sat Sep 06 07:29:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Xenograft
NSCLC
STAT3 inhibitor
STX-0119
Cancer
Language English
License The Author(s) 2019.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c636t-9998caea31a8007c2c69a9c30d1a4da180d09ab47cbc8bb1c96f50ea097720433
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
https://labanimres.biomedcentral.com/articles/10.1186/s42826-019-0030-0
ORCID 0000-0003-3678-2772
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s42826-019-0030-0
PMID 32257917
PQID 2546825169
PQPubID 5068521
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_6421298
doaj_primary_oai_doaj_org_article_9f8931313d0c4cd6853b4271191d482f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7081529
proquest_miscellaneous_2387655271
proquest_journals_2546825169
pubmed_primary_32257917
crossref_primary_10_1186_s42826_019_0030_0
crossref_citationtrail_10_1186_s42826_019_0030_0
springer_journals_10_1186_s42826_019_0030_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-12-21
PublicationDateYYYYMMDD 2019-12-21
PublicationDate_xml – month: 12
  year: 2019
  text: 2019-12-21
  day: 21
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: Seole
PublicationTitle Laboratory animal research
PublicationTitleAbbrev Lab Anim Res
PublicationTitleAlternate Lab Anim Res
PublicationYear 2019
Publisher BioMed Central
BMC
한국실험동물학회
Publisher_xml – name: BioMed Central
– name: BMC
– name: 한국실험동물학회
References RJ Leeman (30_CR10) 2006; 6
DA Frank (30_CR32) 2013; 31
T Ashizawa (30_CR28) 2011; 38
H Yu (30_CR38) 2014; 14
N Li (30_CR35) 2011; 19
M Kujawski (30_CR5) 2008; 118
R Catlett-Falcone (30_CR7) 1999; 10
YH Xu (30_CR26) 2014; 40
L Crino (30_CR22) 2010; 21
I Gkouveris (30_CR2) 2015; 06
K Matsuno (30_CR16) 2010; 1
B Fang (30_CR31) 2014; 6
O Tredan (30_CR36) 2007; 99
M Furqan (30_CR11) 2013; 1
KM Lewis (30_CR19) 2015; 90
H Xin (30_CR40) 2009; 69
KR Hahn (30_CR30) 2017; 33
Y Akiyama (30_CR29) 2017; 190
SL Furtek (30_CR15) 2016; 11
LA Torre (30_CR20) 2015; 65
X Wang (30_CR14) 2012; 41
X Huang (30_CR25) 2013; 31
RL Siegel (30_CR21) 2017; 67
T Chiba (30_CR18) 2016; 1
T Kusaba (30_CR23) 2006; 15
H Yu (30_CR3) 2007; 7
H Yu (30_CR34) 2009; 9
JE Darnell (30_CR4) 2005; 11
T Ashizawa (30_CR27) 2013; 43
E Bournazou (30_CR13) 2013; 2
Q Chen (30_CR17) 2019; 9
H Xiong (30_CR24) 2012; 90
S Choi (30_CR33) 2019; 513
DE Johnson (30_CR1) 2018; 15
RL Carpenter (30_CR12) 2014; 6
R Lai (30_CR9) 2003; 199
J Bollrath (30_CR6) 2009; 15
B Groner (30_CR37) 2008; 19
M Vanneman (30_CR39) 2012; 12
H Lee (30_CR8) 2019; 52
References_xml – volume: 43
  start-page: 219
  issue: 1
  year: 2013
  ident: 30_CR27
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2013.1916
– volume: 69
  start-page: 2506
  issue: 6
  year: 2009
  ident: 30_CR40
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-4323
– volume: 65
  start-page: 87
  issue: 2
  year: 2015
  ident: 30_CR20
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21262
– volume: 19
  start-page: 429
  issue: 4
  year: 2011
  ident: 30_CR35
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.03.018
– volume: 21
  start-page: v103
  issue: Suppl 5
  year: 2010
  ident: 30_CR22
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq207
– volume: 31
  start-page: 4560
  issue: 36
  year: 2013
  ident: 30_CR32
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.52.8414
– volume: 15
  start-page: 91
  issue: 2
  year: 2009
  ident: 30_CR6
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.01.002
– volume: 6
  start-page: 897
  issue: 2
  year: 2014
  ident: 30_CR12
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers6020897
– volume: 9
  start-page: 6424
  issue: 22
  year: 2019
  ident: 30_CR17
  publication-title: Theranostics
  doi: 10.7150/thno.35528
– volume: 10
  start-page: 105
  issue: 1
  year: 1999
  ident: 30_CR7
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80011-4
– volume: 199
  start-page: 84
  issue: 1
  year: 2003
  ident: 30_CR9
  publication-title: J Pathol
  doi: 10.1002/path.1253
– volume: 9
  start-page: 798
  issue: 11
  year: 2009
  ident: 30_CR34
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2734
– volume: 52
  start-page: 415
  issue: 7
  year: 2019
  ident: 30_CR8
  publication-title: BMB Rep
  doi: 10.5483/BMBRep.2019.52.7.152
– volume: 40
  start-page: 311
  issue: 3
  year: 2014
  ident: 30_CR26
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2013.11.012
– volume: 06
  start-page: 709
  issue: 08
  year: 2015
  ident: 30_CR2
  publication-title: J Cancer Ther
  doi: 10.4236/jct.2015.68078
– volume: 1
  start-page: S1
  issue: 31
  year: 2016
  ident: 30_CR18
  publication-title: EC Cancer
– volume: 31
  start-page: 4520
  issue: 36
  year: 2013
  ident: 30_CR25
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.45.6004
– volume: 33
  start-page: 114
  issue: 2
  year: 2017
  ident: 30_CR30
  publication-title: Lab Anim Res
  doi: 10.5625/lar.2017.33.2.114
– volume: 11
  start-page: 595
  issue: 6
  year: 2005
  ident: 30_CR4
  publication-title: Nat Med
  doi: 10.1038/nm0605-595
– volume: 118
  start-page: 3367
  issue: 10
  year: 2008
  ident: 30_CR5
  publication-title: J Clin Invest
  doi: 10.1172/JCI35213
– volume: 15
  start-page: 1445
  issue: 6
  year: 2006
  ident: 30_CR23
  publication-title: Oncol Rep
– volume: 14
  start-page: 736
  issue: 11
  year: 2014
  ident: 30_CR38
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3818
– volume: 11
  start-page: 308
  issue: 2
  year: 2016
  ident: 30_CR15
  publication-title: ACS Chem Biol
  doi: 10.1021/acschembio.5b00945
– volume: 90
  start-page: 182
  issue: 2
  year: 2015
  ident: 30_CR19
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2015.09.014
– volume: 19
  start-page: 341
  issue: 4
  year: 2008
  ident: 30_CR37
  publication-title: Semin Cell Dev Biol
  doi: 10.1016/j.semcdb.2008.06.005
– volume: 41
  start-page: 1181
  issue: 4
  year: 2012
  ident: 30_CR14
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2012.1568
– volume: 2
  start-page: e23828
  issue: 2
  year: 2013
  ident: 30_CR13
  publication-title: JAKSTAT
– volume: 12
  start-page: 237
  issue: 4
  year: 2012
  ident: 30_CR39
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3237
– volume: 7
  start-page: 41
  issue: 1
  year: 2007
  ident: 30_CR3
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1995
– volume: 1
  start-page: 5
  issue: 1
  year: 2013
  ident: 30_CR11
  publication-title: Biomark Res
  doi: 10.1186/2050-7771-1-5
– volume: 15
  start-page: 234
  issue: 4
  year: 2018
  ident: 30_CR1
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2018.8
– volume: 190
  start-page: 20
  year: 2017
  ident: 30_CR29
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2017.07.005
– volume: 90
  start-page: 1037
  issue: 9
  year: 2012
  ident: 30_CR24
  publication-title: J Mol Med
  doi: 10.1007/s00109-012-0869-0
– volume: 38
  start-page: 1245
  issue: 5
  year: 2011
  ident: 30_CR28
  publication-title: Int J Oncol
– volume: 6
  start-page: 231
  issue: 3
  year: 2006
  ident: 30_CR10
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.6.3.231
– volume: 1
  start-page: 371
  issue: 8
  year: 2010
  ident: 30_CR16
  publication-title: ACS Med Chem Lett
  doi: 10.1021/ml1000273
– volume: 513
  start-page: 49
  issue: 1
  year: 2019
  ident: 30_CR33
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2019.03.156
– volume: 99
  start-page: 1441
  issue: 19
  year: 2007
  ident: 30_CR36
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djm135
– volume: 67
  start-page: 7
  issue: 1
  year: 2017
  ident: 30_CR21
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21387
– volume: 6
  start-page: 494
  issue: 1
  year: 2014
  ident: 30_CR31
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers6010494
SSID ssj0000507340
Score 2.2676504
Snippet Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell...
Abstract Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including...
SourceID nrf
doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 30
SubjectTerms Angiogenesis
Annexin V
Antibodies
Apoptosis
Biomedical and Life Sciences
c-Myc protein
Cancer
Cancer therapies
Cell cycle
Cell differentiation
Cell proliferation
Cell survival
Chemoresistance
Chemotherapy
Cyclin D1
Dosage
Gene expression
Gene regulation
Kinases
Leukocytes
Life Sciences
Lung cancer
Medical prognosis
Medical research
Metastases
Myc protein
NSCLC
Poly(ADP-ribose) polymerase
Ribose
Side effects
STAT3 inhibitor
Stat3 protein
STX-0119
Survivin
Transcription
Tumor cell lines
Tumors
Xenograft
Xenografts
수의학
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQJCReEDA-MgYyiCdQNNtxnZi3gTZtSPBCJ028WP5KW21Kqib9_7lz0rLCGC-oD61qW3F9v_Pd1Xc_E_IuVonYy-W1KGMuC69y7WtQd-kL6VzkzGPt8Ndv6uxCfrmcXN646gtzwgZ64GHhjnQNFpXDKzAvfVBgXpwUJfKSBVmJGndfptmNYGpg9Qboys0xJq_UUQd-tsDgWecI7JztGKLE1w_mpVnVt7maf2ZM_nZsmqzR6SPycHQj6fEw_cfkXmyekPs_2vQn-T5x58184VI2Fm1r-n16PC0opmpYrD6nEIeDRDtql-2yb7sFfGoC7dbLlBULDTMIzvs5Dr2GzYB6hMbqI521bUhdnQ1PycXpyfTzWT7eppB7Vag-B0-w8jbagltwEksvvNJW-4IFbmWwvGKBaetk6Z2vnONeq3rComXgIWIBbfGM7DVtE18QGm0pajkJeIiDhXIOgpJaOB61jypEmxG2WVrjR6pxvPHi2qSQo1JmkIYBaSA5KTMsI--3Q5YDz8ZdnT-hvLYdkSI7fQHAMSNwzL-Ak5G3IG1z5RdpPL7PWnO1MhBInBus_xW6ysjhBgxmVO7O4BUCWPGrdEbebJtBLfGsxTaxXUOfAswMstvxjDwfsLOdLu6hJYTJGSl3ULXze3ZbmsU8UX-X4MFNBDz3wwZ_v6b11-U6-B_L9ZI8EKg8XOSCH5K9frWOr8Af693rpHo_AYxSLWA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgExIviO8FBgqIJ1A020mchBe0oU0bEhOCTpp4sfyVttoUhyb9_7lz3U7lY-pDq9pWPnx3_p3v7mdC3rk6EHvprOWVy4rciKwxLah7YfJCa8eowdrhr-fi9KL4cllexg23IaZVrm1iMNTWG9wjP0DediyzFM2n_leGp0ZhdDUeoXGX7IIJrkHOd4-Oz7993-yyUIA7eayKBM0G7F7G0CarxcEA2JujQ91kKOwZ3VqcAoc_LDndov0X_Pw7i_KPUGpYoU4ekgcRWqaHK1l4RO647jG599OHjfMnRJ91s7kOGVqpb9Mfk8NJnmL6hsKK9BR8c5jlIVW970c_zOFXZ9Nh2YdMWWiYgsM-znDoNRiI1KC4LD6mU-9t6KqVfUouTo4nn0-zeMJCZkQuxgzQYW2UUzlTABwrw41oVGNyapkqrGI1tbRRuqiMNrXWzDSiLalTFFAjFtXmz8hO5zu3R1KnKt4WpcXADhbPaXBUWq6Za4wT1qmE0PWrlSbSj-MpGNcyuCG1kKvZkDAbSFhKJU3I-82QfsW9cVvnI5yvTUekzQ5_-MVURi2UTQvwjMHHUlMYKwCr6IJXSHJni5q3CXkLsy2vzDyMx--pl1cLCc7FmcSaYN7UCdlfC4OMCj_IG_FMyJtNM6gqxl9U5_wS-uSw9CDjHUvI85XsbG4X7WoFrnNCqi2p2nqe7ZZuPgt04BWgupLDdT-s5e_mtv77ul7c_hAvyX2OasF4xtk-2RkXS_cK0NeoX0cV-w203SmN
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Li9RAEG5kRfAivs26SiuelGC_0km8rYvLrqAXZ2Hx0vQrM8MuyTDJ_H-rejLR0VWQHBLS1eRRVemvUl1fE_ImVonYy-WNKGOupNd57Rtwd-Wlci5y5rF2-MtXfXahPl8WlyNZNNbC_Jq_55V-3wM8Fhjz1jnaYw7R-e2CS53ysvpk-p3CANdItctb3thzb-RJBP0wnrTr5iZs-ecUyd_ypGn4Ob1P7o24kR5vFf2A3IrtQ3Lne5f-ij8i7rxdLF2afkW7hn6bHc8kxbkZFsvNKQTeoMKe2lW3Grp-CUdtoP1mlabBQsMcovFhgV2vwfupR1tYf6DzrgtJ1NnwmFycfpqdnOXj8gm511IPOUC_yttoJbeACksvvK5t7SUL3KpgecUCq61TpXe-co77WjcFi5YBJMSKWfmEHLRdG58RGm0pGlUEzNpgZZyDKKQRjsfaRx2izQjbvVrjR25xXOLi2qQYo9Jmqw0D2kA2UmZYRt5OXVZbYo1_CX9EfU2CyImdToCpmNHFTN0A9uKwBeaVDxqAiFOiRAa7oCrRZOQ1aNtc-WXqj_t5Z67WBiKHc4MFv6KuMnK0MwYzenNvcM0ALPHVdUZeTc3gh5hcsW3sNiAjYVxBOjuekadb25luFz-aJcTFGSn3rGrvefZb2uUicX2XANkKAdd9t7O_n7f119d1-F_Sz8ldgV7CRS74ETkY1pv4ApDW4F4mH_sBha0epA
  priority: 102
  providerName: Springer Nature
Title Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad
URI https://link.springer.com/article/10.1186/s42826-019-0030-0
https://www.ncbi.nlm.nih.gov/pubmed/32257917
https://www.proquest.com/docview/2546825169
https://www.proquest.com/docview/2387655271
https://pubmed.ncbi.nlm.nih.gov/PMC7081529
https://doaj.org/article/9f8931313d0c4cd6853b4271191d482f
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002547058
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Laboratory Animal Research, 2019, 35(4), , pp.221-229
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9NAEB_OOwRfxG-jZ4nikxJNNskmEUTuyh13wh2iLRy-LPuVtlxJatqC_vfObJJKtYr0ISW72yY7M5nfZHd-A_DS5o7YSwUly2yQxJoHhS7R3BMdJ0rZKNSUO3xxyc_Gycer9GoP-vJW3QQud4Z2VE9q3MzffP_24wMa_Htn8Dl_u0QIzSguLgLS2QAj-AN0TJxisYsO7bdU36jPXYokmjkC-bRb59z5K1ueyhH6o_-pmnIXFv1zS-Vv66rOXZ3egdsdzvSPWsW4C3u2ugc3v9buLfp9UOfVdKbcdi2_Lv0vo6NR7NNeDknp6T4G6ijypS8X9WJVL2f4rTL-cr1w22axYYLR-2pKQ-f4tPA16U7zzp_UtXFdlTQPYHx6MhqeBV25hUDzmK8ChIq5llbGkUQUmWmmeSELHYcmkomRUR6asJAqybTSuVKRLniZhlaGCCEpwzZ-CPtVXdnH4FuZsTJJDa3yUCadwqilZCqyhbbcWOlB2E-t0B0XOZXEmAsXk-RctNIQKA1iLw1F6MGrzZBFS8Txr87HJK9NR-LQdifqZiI6kxRFiVgtwo8JdaINR-CiEpYR451JclZ68AKlLa71zI2n46QW143ASONcUIIwK3IPDntlEL3yCqoxQCnBvPDg-aYZ7ZYWY2Rl6zX2idEPEf1d5MGjVnc2l0sP2QzjaA-yLa3aup_tlmo2ddzgGUK8lOH_vu7179dl_XW6nvzPnT6FW4yMI2IBiw5hf9Ws7TMEZCs1gIPjk8tPnwdwY8iHA_daY-BM7yc3TTCm
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ8ReEPcFBgQEL6BojpPmgoTQBptatlUIOmnai_EtbbUpLkmriT_Fb-QcN-lULnub8tCottvE5-Lv-FxMyCuTucJeMihYaoI4UkmQqwLEPVZRLKUJqcLc4aNB0juOP590T9bIrzYXBsMqW53oFLW2CvfIt7FuO6ZZJvmH6Y8AT41C72p7hMaCLQ7Mzwsw2er3_U9A39eM7e8NP_aC5lSBQCVRMgsAEWVKGBGFAsBSqphKcpGriOpQxFqEGdU0FzJOlVSZlKHKk6JLjaCAlDCRNILfvUHWY8xo7ZD13b3Bl6_LXR0K8CpqsjBBk4Ct0G1cqWGWbNeA9Rka8HmAwhXQlcXQnRkAS1xZFf-Cu39Hbf7hunUr4v4dcruBsv7OgvfukjVT3iM3T63bqL9PZL8cT6SLCPNt4X8b7gwjH8NFBGbA-5NSA1fVvpja6czWE7grtV_Ppy4yFxpGlb2YjXHoOSgkXyF7Vu_8kbXadZVCPyDH1zL3D0mntKXZJL4RKSvirkZHEibrSTCMCiZDkyuTaCM8Qtup5aopd46nbpxzZ_ZkCV9QgwM1sEAq5dQjb5ZDpotaH1d13kV6LTtimW73ha1GvJF6nhcAB0O4NFWx0glgIxmzFIvq6ThjhUdeArX5mZq48fg5svys4mDM9DnmILM888hWywy8UTA1vxQHj7xYNoNqQH-PKI2dQ58IljqssBd65NGCd5aPi3o8BVPdI-kKV628z2pLORm78uMpoMgug_992_Lf5WP9d7oeX_0Sz8mt3vDokB_2BwdPyAZDEQlZwMIt0plVc_MUkN9MPmvEzSffr1vCfwOoAmaC
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJxAviDuBAQHBCyiq46S5ICG0sVUrg2qCTpr2YnxLW22KS9Jq4q_x6zjHTTqVy96mPDSq7Taxz-U7PhcT8spkrrCXDAqWmiCOVBLkqgB2j1UUS2lCqjB3-Msw2T-KPx33jjfIrzYXBsMqW5noBLW2CvfIu1i3HdMsk7xbNGERh7v9D7MfAZ4ghZ7W9jiNJYkcmJ_nYL7V7we7sNavGevvjT7uB80JA4FKomQeADrKlDAiCgUAp1QxleQiVxHVoYi1CDOqaS5knCqpMilDlSdFjxpBATVhUmkEv3uNbKagFeMO2dzZGx5-Xe3wUIBaUZORCVIF7IZe41YNs6RbA-5naMznATJaQNcUozs_ANRdWRX_gr5_R3D-4cZ12rF_m9xqYK2_vaTDO2TDlHfJ9RPrNu3vETkoJ1PposN8W_jfRtujyMfQEYHZ8P601EBhtS9mdja39RTuSu3Xi5mL0oWGcWXP5xMcegbCyVdIqtU7f2ytdl2l0PfJ0ZXM_QPSKW1pHhHfiJQVcU-jUwkT9yQYSQWTocmVSbQRHqHt1HLVlD7HEzjOuDOBsoQvV4PDamCxVMqpR96shsyWdT8u67yD67XqiCW73Re2GvNGAvC8AGgYwqWpipVOACfJmKVYYE_HGSs88hJWm5-qqRuPn2PLTysOhs2AYz4yyzOPbLXEwBthU_ML1vDIi1UziAn0_YjS2AX0iUDtYbW90CMPl7SzelyU6SmY7R5J16hq7X3WW8rpxJUiTwFR9hj879uW_i4e67_T9fjyl3hObgBn88-D4cETcpMhh4QsYOEW6cyrhXkKIHAunzXc5pPvV83gvwGLH2qu
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+STAT3+signaling+induces+apoptosis+and+suppresses+growth+of+lung+cancer%3A+good+and+bad&rft.jtitle=Laboratory+animal+research&rft.au=%EA%B0%95%EC%A3%BC%ED%9D%AC&rft.au=%EC%9E%A5%EC%98%81%EC%88%98&rft.au=%EC%9D%B4%ED%95%98%EC%A0%95&rft.au=%EC%9D%B4%EC%B0%BD%EC%98%81&rft.date=2019-12-21&rft.pub=%ED%95%9C%EA%B5%AD%EC%8B%A4%ED%97%98%EB%8F%99%EB%AC%BC%ED%95%99%ED%9A%8C&rft.issn=1738-6055&rft.eissn=2233-7660&rft.spage=221&rft.epage=229&rft_id=info:doi/10.1186%2Fs42826-019-0030-0&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_6421298
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2233-7660&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2233-7660&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2233-7660&client=summon